Evidence map›Paper›PMID 30936976›Full record

ArticleExperimental and therapeutic medicine2019

Analysis of thrombelastogram-guided medication in patients with coronary heart disease after percutaneous coronary intervention.

Yingbo Li, Hongjin Chang, Lina Ni, Peng Xue, Caixia Li, Lin Yuan, Hailing Cui, Chengyong Yu

Abstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Clinical Significance of Thrombelastography Results in Patients with Lung Adenocarcinoma in Situ Complicated with Type 2 Diabetes.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yingbo LiDepartment of Clinical Laboratory, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China.
Hongjin ChangDepartment of Blood Transfusion, Affiliated Hospital of Jining Medical University, Jining, Shandong 272000, P.R. China.
Lina NiDepartment of Clinical Laboratory, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China.
Peng XueDepartment of Clinical Laboratory, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China.
Caixia LiDepartment of Medical Administration, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China.
Lin YuanDepartment of Clinical Laboratory, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China.
Hailing CuiDepartment of Clinical Laboratory, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China.
Chengyong YuDepartment of Clinical Laboratory, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effects of thrombelastogram-guided (TEG-guided) clopidogrel and aspirin on major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) were investigated. A retrospective analysis was performed on 203 patients undergoing PCI interventional therapy in the Cardiovascular Medicine of Weihai Central Hospital from February 2015 to September 2016. The patients were treated with clopidogrel and aspirin for anti-thrombus therapy. Among them, 104 patients who had TEG detection of anticoagulant effects for guiding medication were the experimental group, and 99 patients without TEG detection for guiding medication the control group. The coagulation function and the platelet inhibition rate of patients after medication were evaluated and compared between the two groups. The incidence of MACE and bleeding events of patients was counted during three months of follow-up. Patients in the experimental group had higher R (coagulation reaction time) value and K (blood clot formation time) value than those in the control group after treatment (P<0.05), and lower MA (maximum amplitude) value than those in the control group (P<0.05). Patients in the experimental group had higher postoperative platelet inhibition rate than those in the control group (P<0.05). Patients in the experimental group had lower incidence of MACE and bleeding events than those in the control group (P<0.05). Coronary heart disease (CHD) patients after PCI with the TEG-guided dose adjustment of clopidogrel have more satisfactory treatment effects than patients without the TEG guidance. TEG makes the treatment of patients more targeted and is worthy of promotion.

Indexed as

aspirinclopidogrelcoronary heart diseasepercutaneous coronary interventionthrombelastogram

Identifiers

PMID30936976
PMCPMC6434236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.